TransCode Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.2M
- Price
- $3.01
- % Change (Daily % change from the live per-ticker quote feed.)
- -6.23%
- Volume
- 21.2K
About
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
Quick stats
Shares outstanding1.1M
Computed float832.6K
Float / shares78.7%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001829635
AI Summary
AI-generated1/9
minorbullishoperations update
Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
TransCode Therapeutics CEO Philippe Calais is scheduled to appear on the RedChip Small Stocks, Big Money show to discuss the company's strategic evolution.
Calais will highlight the advancement of lead candidate TTX-MC138 into a Phase 2a clinical trial targeting ctDNA positive colorectal cancer patients following curative intent therapy.
The discussion covers Phase 1a results that met primary safety endpoints, achieved disease stabilization, and showed no dose-limiting toxicities.
Red flags
- paid / sponsored investor relations television program
- disclosure delivered via third-party marketing firm rather than standard regulatory filing